本文選題：顱內(nèi)感染　切入點：抗菌藥物治療　出處：《中華醫(yī)院感染學(xué)雜志》2016年18期

【摘要】：目的探討碳青酶烯類耐藥腸桿菌(CRE)和碳青酶烯類敏感腸桿菌(CSE)顱內(nèi)感染治療效果和直接經(jīng)濟損失的差異,分析顱內(nèi)感染治療效果的影響因素。方法采用回顧性調(diào)查方法,選取醫(yī)院2014年1月-2015年12月CRE和CSE顱內(nèi)感染患者,按1∶1比例配對,將患者分為CRE組和CSE組,各12例;比較CRE和CSE顱內(nèi)感染治療效果和住院費用的差異,分析耐藥情況和抗菌藥物聯(lián)合使用對治療效果的影響。結(jié)果發(fā)現(xiàn)CRE顱內(nèi)感染治愈率為41.67%,CSE顱內(nèi)感染治愈率為91.67%,兩組差異有統(tǒng)計學(xué)意義(P0.05);CRE組每床日醫(yī)療費用為7 008.82元,CSE組每床日醫(yī)療費用為2 777.75元,兩組差異有統(tǒng)計學(xué)意義(Z=-2.252,P=0.024);碳青酶烯類聯(lián)合其他藥物治療CRE顱內(nèi)感染是常見的組合,治愈率66.67%,CSE顱內(nèi)感染治療以碳青酶烯類單藥治療為主,治愈率為91.67%;鞘內(nèi)局部注射抗菌藥物局部治療,未提高CRE顱內(nèi)感染的治愈率。結(jié)論 CRE顱內(nèi)感染可明顯增加患者的經(jīng)濟損失,臨床治療效果較CSE低,臨床應(yīng)積極采取有效措施進行預(yù)防控制。
[Abstract]:Objective to explore the difference between the therapeutic efficacy and direct economic loss of enterobacter carbene resistance (CRE) and enterobacterium carboxylerenes (CSE) in the treatment of intracranial infection, and to analyze the factors affecting the therapeutic effect of intracranial infection. Methods retrospective investigation was used. From January 2014 to December 2015, the patients with intracranial infection of CRE and CSE were divided into two groups: CRE group and CSE group, according to 1:1 ratio, 12 patients in each group were divided into CRE group and CSE group, and the difference of treatment effect and hospitalization cost between CRE group and CSE group was compared. The effect of drug resistance and combined use of antimicrobial agents on the therapeutic effect was analyzed. The results showed that the cure rate of intracranial infection of CRE was 41.67 yuan, and the cure rate of intracranial infection of CRE was 91.67 yuan. The difference between the two groups was statistically significant (P 0.05). The daily medical cost per bed was 7 008.82 yuan in the CRE group. The daily medical cost per bed in CSE group was 2 777.75 yuan. There was significant difference between the two groups in the treatment of CRE intracranial infection, the cure rate was 66.67%, the cure rate was 66.67%, and the cure rate was 66.67%, the cure rate was 66.67%, the cure rate was 66.67%, and the cure rate was 66.67%, and the cure rate was 66.67%, and the cure rate was 66.67%. The cure rate was 91.67.The local treatment of intrathecal injection of antimicrobial agents did not improve the cure rate of CRE intracranial infection. Conclusion Intracranial CRE infection can significantly increase the economic loss of patients, and the clinical effect is lower than that of CSE. Effective measures should be taken in clinical prevention and control.
【作者單位】： 福建省腫瘤醫(yī)院醫(yī)院感染管理科;中南大學(xué)湘雅醫(yī)院感染控制中心;
【基金】：湖南省自然科學(xué)基金(13JJ6013) 中南大學(xué)湘雅醫(yī)院院內(nèi)臨床基金(2014-11);中南大學(xué)校級大數(shù)據(jù)基金(2014-33)
【分類號】：R446.5

【相似文獻】

相關(guān)期刊論文 前10條

1 蒯守剛;邵海楓;王衛(wèi)萍;范明;黃梅;尤金煒;王穎;;耐碳青酶烯類腸桿菌科細菌的耐藥機制研究[J];中華醫(yī)院感染學(xué)雜志;2010年22期

2 張國偉,明德松,吳一波;4種酶抑制劑分類檢測碳青酶烯酶的研究[J];中華醫(yī)院感染學(xué)雜志;2004年10期

3 明德松,吳一波,朱焱,謝尊金;銅綠假單胞菌耐碳青酶烯類抗菌藥物機制分類檢測的研究[J];中華醫(yī)院感染學(xué)雜志;2005年02期

4 顧怡明;郭麗;張杰;;耐碳青酶烯鮑氏不動桿菌碳青酶烯酶基因型的研究[J];中華醫(yī)院感染學(xué)雜志;2009年13期

5 邱清芳;孫浩仙;邱學(xué)峰;程永娥;任福榮;;銅綠假單胞菌耐碳青酶烯類抗菌藥物機制分類檢測的研究[J];醫(yī)學(xué)檢驗與臨床;2007年04期

6 邱清芳;;銅綠假單胞菌耐碳青酶烯類抗菌藥物機制分類檢測的研究[J];中國實驗診斷學(xué);2007年08期

7 邱清芳;;銅綠假單胞菌耐碳青酶烯類抗菌藥物機制分類檢測的研究[J];醫(yī)學(xué)檢驗與臨床;2007年05期

8 李靜;胡志東;;產(chǎn)碳青酶烯酶肺炎克雷伯菌的檢測與分析[J];中華醫(yī)院感染學(xué)雜志;2010年15期

9 郭普;喬艷;鐘政榮;沈繼錄;李峰;;鮑氏不動桿菌對亞胺培南耐藥性及碳青酶烯酶基因型分析[J];中華醫(yī)院感染學(xué)雜志;2010年07期

10 陳萍;劉丁;方清永;王政;王豪;成瑤;南玲;黃慶玲;;耐碳青酶烯類腸桿菌科細菌醫(yī)院感染危險因素分析[J];重慶醫(yī)學(xué);2014年26期

相關(guān)會議論文 前3條

1 王進;肖永紅;劉遠程;劉健;薛峰;楊維維;郝鳳蘭;;銅綠假單胞菌對碳青酶烯類藥物的體外抗菌研究[A];第六屆全國抗菌藥物臨床藥理學(xué)術(shù)會議論文集[C];2006年

2 茹納丹;呂火祥;胡慶豐;魏取好;沈蓓瓊;;改良Hodge試驗陽性腸桿菌科細菌對碳青酶烯類藥物的耐藥性檢測方法比較[A];浙江省第十九屆農(nóng)村衛(wèi)生改革與發(fā)展學(xué)術(shù)會議大會論文集[C];2011年

3 彭俊華;張媛媛;付藏紅;張峰;馬芳軍;;鮑曼不動桿菌耐藥表型及碳青酶烯酶OXA基因分析[A];中華醫(yī)學(xué)會第八次全國檢驗醫(yī)學(xué)學(xué)術(shù)會議暨中華醫(yī)學(xué)會檢驗分會成立30周年慶典大會資料匯編[C];2009年

，

本文編號：1690188